

India Equity Research | Retail August 13, 2021 **Result Update**

Page Industries

Refer to important disclosures at the end of this report

Growth outlook remains upbeat

- Q1 performance was slightly better, with revenue recovery at 60% (10% ahead of estimates) and EBITDA margins at 6.8%. Sales grew 76% yoy to Rs5bn on low comparables, but declined 43% qoq due to the Covid-induced restrictions.
- Management indicated that Jul'21 sales recovery is healthy and similar to Apr'21. Strong
 growth plans in Kidswear/Athleisure and aggressive network expansion into Tier-3/4 and
 rural towns offer good visibility of mid-teens growth ahead.
- Margin trends are healthy with better cost control despite a steep increase in RM prices and relatively lower price hikes (~7-8% vs. 20% of its peers in the economy category).
 PAG hinted at returning to 21%+ margins ahead, as sales recover.
- Strong on-the-ground execution during lockdowns and focus on fast-growing categories (Kids/Athleisure) and strong network expansion keep us positive on PAG. Maintain Buy with a revised TP of Rs37,500 ((55x Sep'23E EPS)

Relatively better recovery; growth outlook remains upbeat: Revenues grew ~76% yoy in Q1, led by 70% volume growth on a low base and 4% realization growth. Revenue recovery of ~60% was better than ~35% recovery seen last year, both compared to pre-Covid levels. Better volumes were driven by ~20% network expansion, higher footfalls and strong online growth (up 250%). Among segments, Athleisure, Kids and Women innerwear saw stronger growth than Men's innerwear. While disruptions continued in Jul'21, PAG indicated a healthy recovery to Apr-21 levels (June was ~25% lower). Management remains upbeat on growth prospects, helped by market share gains with a robust supply-chain during lockdowns, large opportunities in Kidswear/Athleisure, rural expansion and online. Jockey Junior now has a separate 200-member salesforce and athleisure has seen healthy new customer acquisitions on WFH trends. Since FY20, PAG's EBO/MBO network has expanded strongly by 20-25%, with ~50% of that added in Tier-2/3/4 and rural markets (now forming ~50% of sales).

Margins to recover to ~21% levels: EBITDA margins of 6.8% were better than expected, supported by cost control and higher gross margins (up ~1,000bps; ex-subcon expenses) on better manufacturing overhead absorption. The commentary was strong with PAG indicating 21%+ margins on full recovery ahead. PAG has also been able to contain the impact of strong increase in RM prices with better cost control – has effected only ~4% price hike (cumulative 7-8%) vs. ~20% cumulative hike by peers that operate in the economy segment.

Expect a strong recovery ahead; Buy: With manufacturing operations normalized and the store network fully operational, we expect a strong recovery ahead. PAG's strong product expansion plans and fast scale-up of distribution network provide better visibility of mid-teens growth sustaining ahead. Valuations at 52x FY23E EPS are at a discount to other high-growth peers. Maintain Buy with a revised TP of Rs37,500 based on 55x Sep'23E EPS.

Please see our sector model portfolio (Emkay Alpha Portfolio): Consumer Goods & Retail (Page 7)

Financial Snapshot (Standalone)

(Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
Revenue	29,454	28,330	35,657	44,588	51,168
EBITDA	5,326	5,266	7,119	9,880	11,600
EBITDA Margin (%)	18.1	18.6	20.0	22.2	22.7
APAT	3,432	3,406	4,824	6,897	8,143
EPS (Rs)	307.7	305.3	432.5	618.4	730.0
EPS (% chg)	(12.9)	(0.8)	41.6	43.0	18.1
ROE (%)	43.0	40.0	51.1	61.4	58.4
P/E (x)	105.2	106.0	74.9	52.4	44.3
EV/EBITDA (x)	67.6	67.7	50.1	36.1	30.6
P/BV (x)	44.0	40.8	36.0	29.0	23.4

Source: Company, Emkay Research



СМР	Target Price
Rs 32,374 as of (August 12, 2021)	Rs 37,500 (▲) 12 months
Rating	Upside
BUY (∎)	15.8 %

Change in Estimates

Change in Estimate	63		
EPS Chg FY22E/FY	′23E (%))	(9)/(2)
Target Price change	e (%)		2.7
Target Period (Mont	hs)		12
Previous Reco			BUY
Emkay vs Consens	sus		
EPS E	stimates	\$	
	FY2	2E	FY23E
Emkay	43	2.5	618.4
Consensus	42	7.7	550.0
Mean Consensus T	P (12M)	Rs	30,483
Stock Details			
Bloomberg Code			PAG IN
Face Value (Rs)			10
Shares outstanding	(mn)		11
52 Week H/L	33	3,989	/ 17,685
M Cap (Rs bn/USD	bn)	36	1 / 4.86
Daily Avg Volume (r	nos.)		30,573
Daily Avg Turnover	(US\$ mr	ı)	12.8
Shareholding Patte	ern Jun	'21	
Promoters			47.9%
Flls			23.6%
DIIs			18.0%
Public and Others			10.5%
Price Performance		C M	4014
(%) 1M	3M	6M 5	12M 70
Absolute (2) Rel. to Nifty (7)	15 3		18
	-	(2)	10
Relative price char 33400 Rs	τ		<u>ж.</u> г 30
30340 - N	AL.A	Abort	- 22
27280 -	' אויי	1	14
24220	, I.		- 6
21160			2
18100		,	-10
Aug-20 Oct-20 Dec-20 ——— Page Industries (LH			-21 Aug-21 Nifty (RHS)
Source: Bloomberg	3)	- Rei la	niity (RH3)
This report is solely prod following person(s) are re of the recommendation:			
Ashit Desai			
ashit.desai@emkayo	global.co	m	
+91 22 6612 1340			
Devanshu Bansal			
devanshu.bansal@e	emkayglo	bal.co	om

+91 22 6612 1385

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.


Story in Charts

additions, athleisure traction and strong online growth 9.3 8.8 100 10.0 8.3 7.8 7.9 7.4 8.2 8.0 7.4 76 6.9 50 61 5.4 6.0 5.0 0 28 4.0 -50 2.0 0.0 -100 o o o o Q1FY20 **Q2FY20** Q3FY20 **Q4FY20** Q1FY22 Q1FY2 O2FY2 Q3FY2 Q4FY2 Q4FY ř Q2FY Q3FY δ Sales (Rs bn) - LHS Sales growth (%) - RHS

Exhibit 1: Better recovery at ~60% vs. ~35% a year ago on outlet

Source: Company, Emkay Research

Exhibit 3: Volume grew 70% on new outlet additions, better traction in athleisure/women-innerwear and strong online growth




Source: Company, Emkay Research

Exhibit 5: Employee costs increased (as % of sales) due to lower revenues in Q1FY22




Source: Company, Emkay Research

Exhibit 2: Low absorption of wages and other overheads due to lower revenues led to lower margins (qoq)




Source: Company, Emkay Research

Exhibit 4: Trade incentives remained lower relative to pre-Covid levels, indicating lower trade discounting



Source: Company, Emkay Research

Exhibit 6: Page 1-yr forward PE chart



Source: Company, Emkay Research,*Mean is FY13-18 to remove COVID-impact

70

Exhibit 7: Actual vs. Estimates (Q1FY22)

Rs mn	Astual	Estimates	Consensus	% var	iation	Comment
K3 IIII	Actual	(Emkay)	Estimates	Emkay	Consensus	Comment
Revenues	5,015	4,580	5,481	9.5%	-8.5%	Revenues were better than expected
EBITDA	342	170	470	101.0%	-27.2%	Better recovery and cost savings led to better margins
EBITDA margin (%)	6.8%	3.7%	8.6%	310	-176	
APAT	109	11	145	866.9%	-24.5%	Strong revenues and margins led to better profits

Source: Company, Emkay Research

Exhibit 8: Quarterly performance (standalone)

Y/E, Mar (Rs mn)	Q1FY21	Q2FY21	Q3FY21	Q4FY21	Q1FY22	YoY (%)	QoQ (%)
Operating Income	2,848	7,403	9,271	8,808	5,015	76.1	-43.1
Expenditure	3,195	5,749	7,009	7,110	4,673	46.3	-34.3
Consumption of RM	1,478	3,297	4,131	3,733	2,120	43.4	-43.2
as % of sales	51.9	44.5	44.6	42.4	42.3		
Employee Cost	1,229	1,299	1,462	1,648	1,527	24.3	-7.3
as % of sales	43.1	17.5	15.8	18.7	30.4		
Other expenditure	488	1,153	1,417	1,729	1,026	110.2	-40.6
as % of sales	17.1	15.6	15.3	19.6	20.5		
EBITDA	-347	1,654	2,261	1,698	342	-198.5	-79.9
Depreciation	160	157	156	156	159	-0.9	2.1
EBIT	-508	1,497	2,105	1,542	183	-136.1	-88.1
Other Income	61	37	42	56	36	-41.2	-36.0
Interest	77	75	74	72	73	-4.2	2.6
РВТ	-524	1,459	2,073	1,526	145	-127.7	-90.5
Total Tax	-128	350	536	371	36	-127.8	-90.4
APAT	-396	1,109	1,537	1,156	109	-127.7	-90.5
Minority Interest	0	0	0	0	0		
APAT (after minority)	-396	1,109	1,537	1,156	109	-127.7	-90.5
Extraordinary Items	0	0	0	0	0		
Reported PAT	-396	1,109	1,537	1,156	109	-127.7	-90.5
Adjusted EPS (Rs)	-35.5	99.4	137.8	103.6	9.8	-127.7	-90.5

Margins (%)	Q1FY21	Q2FY21	Q3FY21	Q4FY21	Q1FY22	(bps)	(bps)
Gross margin	48.1	55.5	55.4	57.6	57.7	960	10
EBIDTA	-12.2	22.3	24.4	19.3	6.8	1,900	-1,250
EBIT	-17.8	20.2	22.7	17.5	3.6	2,150	-1,390
EBT	-18.4	19.7	22.4	17.3	2.9	2,130	-1,440
PAT	-13.9	15.0	16.6	13.1	2.2	1,610	-1,090
Effective Tax rate	24.5	24.0	25.8	24.3	24.6	10.0	30.0

Source: Company, Emkay Research

Exhibit 9: Changes in estimates

Y/E Mar (Rs mn)		FY22E			FY23E			FY24E	
	Earlier	Revised	% Change	Earlier	Revised	% Change	Earlier	Revised	% Change
Revenues	37,153	35,657	(4.0)	44,764	44,588	(0.4)	51,341	51,168	(0.3)
EBITDA	7,772	7,119	(8.4)	10,053	9,880	(1.7)	11,712	11,600	(1.0)
EBITDA Margin (%)	20.9	20.0	-100 bps	22.5	22.2	-30 bps	22.8	22.7	-10 bps
APAT	5,308	4,824	(9.1)	7,023	6,897	(1.8)	8,222	8,143	(1.0)
EPS (Rs)	475.9	432.5	(9.1)	629.6	618.4	(1.8)	737.1	730.0	(1.0)

Source: Company, Emkay Research

Exhibit 10: Peer comparison

Companies	Price	Мсар	Deee	Target		EPS (Rs)			P/E (x)		EV /	EBITDA	(x)
companies	(Rs)	(Rs bn)	Reco	Price (Rs)	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E
ABFRL	208	186	Buy	250	-1.5	3.3	4.8	NA	62.5	43.3	19.3	11.2	9.3
Jubilant FoodWorks	3,672	485	Buy	3,400	38.4	54.0	64.8	95.7	68.0	56.6	41.7	32.3	27.2
Page Industries	32,981	368	Buy	37,500	432.5	618.4	730.0	76.3	53.3	45.2	51.1	36.8	31.1
Titan Company	1,789	1,589	Buy	2,000	24.2	32.3	39.0	73.9	55.4	45.9	47.0	36.1	29.9
Westlife Development	499	78	Buy	630	0.0	4.0	6.4	NA	124.0	77.6	39.9	24.3	19.5
TCNS Clothing	547	34	Buy	800	-4.3	14.1	25.3	NA	38.9	21.6	40.1	11.5	7.6

Source: Company, Emkay Research

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Key Financials (Standalone)

Income Statement

Y/E Mar (Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
Revenue	29,454	28,330	35,657	44,588	51,168
Expenditure	24,128	23,064	28,538	34,708	39,568
EBITDA	5,326	5,266	7,119	9,880	11,600
Depreciation	614	629	689	760	855
EBIT	4,712	4,637	6,429	9,120	10,745
Other Income	246	195	246	296	355
Interest expenses	339	297	227	194	214
РВТ	4,620	4,534	6,449	9,221	10,886
Тах	1,188	1,128	1,625	2,324	2,743
Extraordinary Items	0	0	0	0	0
Minority Int./Income from Assoc.	0	0	0	0	0
Reported Net Income	3,432	3,406	4,824	6,897	8,143
Adjusted PAT	3,432	3,406	4,824	6,897	8,143

Balance Sheet

Y/E Mar (Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
Equity share capital	112	112	112	112	112
Reserves & surplus	8,087	8,737	9,921	12,339	15,329
Net worth	8,199	8,849	10,033	12,450	15,441
Minority Interest	0	0	0	0	0
Loan Funds	1,652	1,270	1,330	1,413	1,467
Net deferred tax liability	2	0	0	0	0
Total Liabilities	9,853	10,119	11,362	13,863	16,908
Net block	4,055	3,863	4,274	4,814	5,259
Investment	0	0	0	0	0
Current Assets	10,787	12,857	14,413	17,447	21,258
Cash & bank balance	1,169	4,350	4,253	4,499	6,678
Other Current Assets	0	0	0	0	0
Current liabilities & Provision	5,277	6,879	7,602	8,677	9,887
Net current assets	5,510	5,978	6,810	8,771	11,370
Misc. exp	0	0	0	0	0
Total Assets	9,853	10,119	11,362	13,863	16,908

Cash Flow

Y/E Mar (Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
PBT (Ex-Other income) (NI+Dep)	4,620	4,534	6,449	9,221	10,886
Other Non-Cash items	0	0	0	0	0
Chg in working cap	741	2,713	(930)	(1,714)	(420)
Operating Cashflow	4,755	6,848	4,564	5,841	8,436
Capital expenditure	(564)	(229)	(800)	(1,000)	(1,000)
Free Cash Flow	4,192	6,619	3,764	4,841	7,436
Investments	0	0	0	0	0
Other Investing Cash Flow	0	0	0	0	0
Investing Cashflow	(317)	(34)	(554)	(704)	(645)
Equity Capital Raised	0	0	0	0	0
Loans Taken / (Repaid)	(457)	(268)	70	70	70
Dividend paid (incl tax)	(2,716)	(2,788)	(3,640)	(4,480)	(5,152)
Other Financing Cash Flow	(355)	(436)	(487)	(481)	(529)
Financing Cashflow	(3,709)	(3,633)	(4,107)	(4,891)	(5,611)
Net chg in cash	729	3,181	(97)	246	2,180
Opening cash position	440	1,169	4,350	4,253	4,499
Closing cash position	1,169	4,350	4,253	4,499	6,678

Source: Company, Emkay Research

Profitability (%)	FY20	FY21	FY22E	FY23E	FY24E
EBITDA Margin	18.1	18.6	20.0	22.2	22.7
EBIT Margin	16.0	16.4	18.0	20.5	21.0
Effective Tax Rate	25.7	24.9	25.2	25.2	25.2
Net Margin	11.7	12.0	13.5	15.5	15.9
ROCE	60.2	56.0	70.7	83.8	79.6
ROE	43.0	40.0	51.1	61.4	58.4
RolC	57.2	66.8	104.4	114.6	112.9
Per Share Data (Rs)	FY20	FY21	FY22E	FY23E	FY24E
EPS	307.7	305.3	432.5	618.4	730.0
CEPS	362.7	361.7	494.3	686.5	806.7
BVPS	735.1	793.3	899.5	1,116.2	1,384.3
DPS	202.0	250.0	326.3	401.6	461.9
Moluctions (v)	51/20	EV04	FV00F	FV02F	EV04E
Valuations (x) PER	FY20 105.2	FY21 106.0	FY22E 74.9	FY23E 52.4	FY24E 44.3
P/CEPS	90.9	91.2	66.7	48.0	44.3
P/BV	90.9 44.0	40.8	36.0	48.0 29.0	23.4
EV / Sales	12.4	40.8	10.2	29.0	7.0
EV / EBITDA	67.6	67.7	50.1	36.1	30.6
Dividend Yield (%)	0.6	0.8	1.0	1.2	1.4
	0.0	0.0	1.0	1.2	1.4
Gearing Ratio (x)	FY20	FY21	FY22E	FY23E	FY24E
Net Debt/ Equity	(0.1)	(0.5)	(0.4)	(0.4)	(0.4)
Net Debt/EBIDTA	(0.2)	(0.8)	(0.6)	(0.5)	(0.6)
Working Cap Cycle (days)	53.8	21.0	26.2	35.0	33.5
Growth (%)	FY20	FY21	FY22E	FY23E	FY24E
Revenue	3.3	(3.8)	25.9	25.0	14.8
EBITDA	(13.7)	(1.1)	35.2	38.8	17.4
EBIT	(19.6)	(1.6)	38.7	41.9	17.8
PAT	(12.9)	(0.8)	41.6	43.0	18.1
Quarterly (Rs mn)	Q1FY21	Q2FY21	Q3FY21	Q4FY21	Q1FY22
. ,	2.848	7.403	9.271	8.808	5.015
Revenue	2,848 (348)	7,403 1 653	9,271 2 261	8,808 1 698	
Revenue EBITDA	(348)	1,653	2,261	1,698	342
Revenue EBITDA EBITDA Margin (%)	(348) (12.2)	1,653 22.3	2,261 24.4	1,698 19.3	342 6.8
Revenue EBITDA EBITDA Margin (%) PAT	(348) (12.2) (396)	1,653 22.3 1,109	2,261 24.4 1,537	1,698 19.3 1,155	5,015 342 6.8 109 9 8
Revenue EBITDA EBITDA Margin (%) PAT EPS (Rs)	(348) (12.2)	1,653 22.3	2,261 24.4	1,698 19.3	342 6.8
Revenue EBITDA EBITDA Margin (%) PAT EPS (Rs)	(348) (12.2) (396)	1,653 22.3 1,109	2,261 24.4 1,537	1,698 19.3 1,155	342 6.8 109 9.8
Revenue EBITDA EBITDA Margin (%) PAT EPS (Rs) Source: Company, Emkay Research	(348) (12.2) (396) (35.5)	1,653 22.3 1,109 99.4	2,261 24.4 1,537 137.8	1,698 19.3 1,155 103.6	342 6.8 109 9.8 Jun-21
Revenue EBITDA EBITDA Margin (%) PAT EPS (Rs) Source: Company, Emkay Research Shareholding Pattern (%) Promoters	(348) (12.2) (396) (35.5) Jun-20	1,653 22.3 1,109 99.4 Sep-20	2,261 24.4 1,537 137.8 Dec-20	1,698 19.3 1,155 103.6 Mar-21	342 6.8 109
Revenue EBITDA EBITDA Margin (%) PAT EPS (Rs) Source: Company, Emkay Research Shareholding Pattern (%)	(348) (12.2) (396) (35.5) Jun-20 48.3	1,653 22.3 1,109 99.4 Sep-20 48.3	2,261 24.4 1,537 137.8 Dec-20 48.3	1,698 19.3 1,155 103.6 Mar-21 48.3	342 6.8 109 9.8 Jun-21 47.9


Source: Capitaline

RECOMMENDATION HISTORY TABLE

Date	Closing Price	ТР	Period (months)	Rating	Analyst
28-May-21	31,362	36,500	12m	Buy	Ashit Desai
11-Feb-21	30,764	28,000	12m	Hold	Ashit Desai
13-Nov-20	21,924	19,250	12m	Hold	Ashit Desai
03-Sep-20	19,163	17,800	12m	Hold	Ashit Desai
24-Jun-20	20,754	17,500	12m	Hold	Ashit Desai
14-Apr-20	16,498	18,200	12m	Hold	Ashit Desai
08-Apr-20	16,757	18,200	12m	Hold	Ashit Desai
14-Feb-20	22,447	21,500	12m	Hold	Ashit Desai
25-Dec-19	21,930	23,000	12m	Hold	Ashit Desai
15-Nov-19	23,762	23,000	12m	Hold	Ashit Desai
20-Sep-19	22,633	22,200	12m	Hold	Ashit Desai
08-Aug-19	18,481	18,400	12m	Hold	Ashit Desai
24-May-19	21,944	23,000	12m	Hold	Ashit Desai
09-Apr-19	24,577	26,000	12m	Hold	Ashit Desai
14-Feb-19	23,990	26,000	12m	Hold	Ashit Desai
15-Nov-18	25,601	26,600	12m	Hold	Ashit Desai
13-Aug-18	32,392	30,500	12m	Hold	Ashit Desai

RECOMMENDATION HISTORY CHART





Source: Company, Emkay Research



Analyst: Ashit Desai

Contact Details

ashit.desai@emkayglobal.com

+91 22 6612 1340

Sector

Consumer Goods & Retail

Analyst bio

Ashit Desai holds a PGDM and FRM (US GARP) with 13 years of research experience on the sell side. His team currently covers 24 stocks in the Indian Consumer and Retail space.

Emkay Alpha Portfolio – Consumer Goods & Retail

EAP sector portfolio

Company Name	BSE200 Weight	EAP Weight	OW/UW (%)	OW/UW (bps)	EAP Weight (Normalised)
Consumer Goods & Retail	10.41	10.41	0%	0	100.00
Asian Paints	1.45	0.52	-64%	-92	5.03
Berger Paints	0.21	0.00	-100%	-21	0.00
Britannia Industries	0.46	0.55	19%	9	5.29
Colgate-Palmolive	0.24	0.26	11%	3	2.54
Dabur India	0.35	0.39	11%	4	3.75
Emami	0.13	0.13	4%	0	1.27
Godrej Consumer Products	0.40	0.43	6%	3	4.09
Hindustan Unilever	2.30	1.76	-24%	-54	16.88
ITC	1.97	2.04	4%	8	19.63
Marico	0.29	0.31	6%	2	2.94
Nestle India	0.70	0.52	-26%	-18	4.98
Pidilite Industries	0.37	0.00	-100%	-37	0.00
Radico Khaitan	0.00	0.32	NA	32	3.03
United Breweries	0.10	0.51	395%	41	4.91
United Spirits	0.00	0.32	NA	32	3.03
Varun Beverages	0.12	0.13	7%	1	1.22
ABFRL	0.07	0.17	154%	11	1.67
Jubilant FoodWorks	0.25	0.27	8%	2	2.56
Page Industries	0.20	0.32	57%	11	3.05
Shoppers Stop*	0.00	0.00	NA	0	0.00
Titan Company	0.81	1.03	28%	23	9.92
TCNS Clothing	0.00	0.19	NA	19	1.87
Westlife Development	0.00	0.25	NA	25	2.36
Cash	0.00	0.00	NA	0	0.00
Source: Emkay Research					

Source: Emkay Research

* Not under coverage: Equal Weight

High Conviction/Strong Over Weight

Sector portfolio NAV


	Base					Latest
-	1-Apr-19	12-Aug-20	10-Feb-21	12-May-21	12-Jul-21	11-Aug-21
EAP - Consumer Goods & Retail	100.0	107.0	121.4	120.2	131.6	132.7
BSE200 Neutral Weighted Portfolio (ETF)	100.0	101.1	116.3	115.3	125.1	126.0
*Performance measurement hase date 1 st Anril 2010						

*Performance measurement base date 1st April Source: Emkay Research

Price Performance (%)

	1m	3m	6m	12m
EAP - Consumer Goods & Retail	0.8%	10.3%	9.2%	23.9%
BSE200 Neutral Weighted Portfolio (ETF)	0.7%	9.3%	8.4%	24.7%
Source: Emkay Research				

NAV chart



Source: Emkay Research

Please see our model portfolio (Emkay Alpha Portfolio): <u>Nifty</u> Please see our model portfolio (Emkay Alpha Portfolio): <u>SMID</u> "Emkay Alpha Portfolio – SMID and Nifty are a supporting document to the Emkay Alpha Portfolios Report and is updated on regular intervals"s

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.	
BUY	Over 15%	
HOLD	Between -5% to 15%	
SELL	Below -5%	
SELL	Below -5%	

Completed Date: 13 Aug 2021 03:04:53 (SGT) Dissemination Date: 13 Aug 2021 03:05:53 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

• This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.

• Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

Disclaimer for U.S. persons only: This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investors.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate¹ does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of August 13, 2021
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report
- Disclosure of previous investment recommendation produced:
 EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research
- 3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of August 13, 2021.
- 5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the August 13, 2021
- 6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
- 8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the August 13, 2021

RESTRICTIONS ON I	
General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6 th Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

Emkay Global Financial Services Ltd. CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com